OR WAIT null SECS
February 05, 2026
Video
The DROP-FPF Phase 3b trial will use automated HRCT biomarkers to assess whether early treatment with nerandomilast can slow disease progression before lung function declines.
February 03, 2026
Article
January 2025 saw new data and guidelines in asthma, COPD, and pulmonary fibrosis.
January 23, 2026
GRI-0621 shows promise as a safe, effective treatment for idiopathic pulmonary fibrosis, improving biomarkers and lung function in a Phase 2a trial.
January 12, 2026
Patients with idiopathic pulmonary fibrosis treated with the STAT3 inhibitor TTI-101 had greater reductions in lung fibrosis scores and IL-6 levels than placebo at 12 weeks.
January 07, 2026
The pulmonology year in review highlights FDA approvals and pivotal data readouts.
October 24, 2025
October 22, 2025
Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.
October 14, 2025
Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.
October 12, 2025
An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.
October 09, 2025
The therapy was well-tolerated in the phase 2a ENV-IPF-101 trial, with mostly mild-to-moderate TEAEs related to treatment.
